How UFlex turns the data from its film lines, converting plants, Asepto fillers, chemicals units and engineering works — across nine countries — into one trusted picture, and into the decisions that compound into shareholder value.
A multinational packaging group usually can't answer a simple question the same way twice across films, converting, aseptic and eight overseas entities. UFlex can — because every number is unified into one governed truth, then served as the exact answer each leader needs to act.
Each business and overseas entity keeps its own books. A simple question — “what's our margin?” — returns a different number from each system, days later.
Data is resolved, federated and defined once — so the same question returns the same trusted number, live, for everyone.
Sign in as any leader and the cockpit becomes theirs: their queue, their views, their guided path from question to decision. Here is what that looks like.
Films, converting, aseptic, chemicals and engineering run on SAP plus eight overseas entity ERPs, plant MES and order desks — no single, trustworthy read on whether the value-added shift and the deleverage plan are working.
One live enterprise picture and a ranked queue of the highest-value moves across the four businesses and nine plant countries.
Walks into the board meeting with the answer — not a three-day consolidation pull.
The UFlex thesis: shift the mix from cyclical commodity films to value-added — Asepto, specialty & PCR — the four pillars, the value levers, how the group is performing, the P&L & cash, the margin journey by business, and the shareholder value it creates.
Margin quality (two EBITDA definitions), 92-day DSO working capital and 4.35× net debt/EBITDA are buried across entity ledgers and FX workpapers.
P&L, working capital, covenant headroom and the deleverage glide path in one governed pane — plus an agentic scenario planner.
Sees the capex-to-volume conversion and the cash to fund the FY27 paydown in seconds.
Earnings to cash to value: the consolidated P&L, resin-cost & inventory working capital, the deleverage path off 4.35× net debt/EBITDA after the capex cycle, business economics, and the listed-company valuation view.
Hard to know if the films-cycle recovery, Asepto and circularity are compounding shareholder value — and how a ~₹3,416 Cr market cap at 0.22× sales reads against packaging peers.
The value-creation plan, EBITDA quality and the EV / market-cap bridge, governance-grade — with the leverage trend tracked honestly.
Reads the recovery, the debt walk and the re-rating case at a glance.
Is the thesis compounding shareholder value: the data mesh behind the numbers, the three lenses, the footprint, the deleverage & margin levers, and the market-cap / EV bridge behind the ~0.22×-sales re-rating case.
Eight overseas films plants report through separate entity ERPs — utilization, tariffs and FX effects surface weeks late and never in one view.
The nine-country films network live: utilization by plant, the Alox / value-added mix, tariff & FX exposure and where the next order lands best.
Sees where the global network is winning — and which line needs volume this quarter.
Lift the films business above the commodity cycle — Alox, high-barrier and PCR specialty films plus recycling leadership: where the demand signals are, the capex behind them, the businesses they join, the program book, qualification with global CPGs, and how they lift blended margin.
Converting throughput, CPG dispatch windows, recycling volumes and plant utilization surface too late, plant by plant.
Live line utilization, first-pass quality, on-time dispatch, EPR / Project Plastic Fix progress and the cost discipline that carries the cycle.
Runs the plants without firefighting — lines full, dispatch on time, trim recycled.
Sense → decide → act across the films lines, converting plants and Asepto: the towers, the agents that act, delivery & quality, the workforce, and resin & supply risk.
Asepto's pack volumes, Sanand capacity, the Egypt greenfield and the account pipeline against Tetra Pak & SIG each live in their own tracker.
The aseptic ramp (7.97 bn packs on 12 bn capacity, Egypt doubling it to 24 bn), account wins by category and commissioning milestones in one place.
Sees where Asepto is winning volume and price — and where the next pack lands.
The UFlex thesis: shift the mix from cyclical commodity films to value-added — Asepto, specialty & PCR — the four pillars, the value levers, how the group is performing, the P&L & cash, the margin journey by business, and the shareholder value it creates.
Specialty-film NPD, CPG qualifications and the films order book sit apart from the commodity-spread reality the lines actually face.
Funnel → qualification → specialty program wins (Alox, F-TPM, Asclepius PCR) and the premium mix that lifts films margin above the cycle.
Knows where the next qualified program comes from and defends the premium book.
Lift the films business above the commodity cycle — Alox, high-barrier and PCR specialty films plus recycling leadership: where the demand signals are, the capex behind them, the businesses they join, the program book, qualification with global CPGs, and how they lift blended margin.
Ashok Chaturvedi runs UFlex on four priorities. Each pillar has concrete levers, a standing AI agent (or desk) working it, and a live goal with a target — so the thesis is measurable, not a slogan.
Shift revenue from commodity films to value-added — laminates & pouches, holography, Alox / high-barrier and PCR specialty — 33% of revenue today, 40% the target.
Scale India's first domestic aseptic brand — 7.97 bn packs sold on Sanand's 12 bn capacity; the Egypt greenfield doubles it to 24 bn.
Project Plastic Fix — 586 mn PCR bottles and 10,237 MT of MLP processed in FY26 — riding the EPR recycled-content mandates as a demand tailwind.
Unwind 4.35× net debt/EBITDA — it ROSE from 3.73× funding ₹2,044 Cr of capex — via FY27 volume on commissioned assets, capex moderation and working capital.
The ontology is the model behind the truth: ten classes, one keystone. The plant / line is where business, leader, legal entity and geography reconcile — so a number computed anywhere foots everywhere.
A 360 assembles everything the platform knows about one subject — graph context, governed metrics, external signals — into one role-ready surface a person and an agent read the same way.
One spine shows the value, the conversion, the days and the leakage at every handoff — from resin to collected cash, with film-stock inventory (~97 days) and aged receivables at each step. The biggest pools: finished-film inventory and the ₹700 Cr of AR past 60 days.
The value-added shift only works if the ₹2,044 Cr capex program converts to volume and the thesis is provable — and only matters if the numbers tie out. A standing reconciliation harness proves each metric equals the sum of its parts.
Pick a leader and walk their journey, ask the cockpit a question, or look under the hood.